Helthcare new gold mine?
written by Q1 Publishing:
The change we’ll look at today is going to be a very big change. When I say big – mean big. We’ll be looking at a change which has the potential to turn the $500 billion pharmaceutical industry completely upside down.
..There’s a lot that goes into developing a new drug. Lately, Big Pharma has slowed down developing new drugs. Big Pharma’s drug pipelines are getting smaller. In other words, they have very few new drugs in development. To make matters worse, some of their key cash cow drugs are going “off patent” in the next few years…
..Personalized medicine is one of the most interesting emerging technologies affecting the healthcare sector. The potential is practically unlimited…
Personalized Medicine 101:
How would we be able to categorize everyone? How would we be able to tell whether a particular drug or solution would work just for them? How would we be able to predict which side effects folks in each group would suffer from?
There were just too many questions and not nearly enough answers.
That all changed in 1990. The answers to all those questions were on the way once the U.S. Human Genome Project (HGP) kicked off. The HGP set out to map the entire genome. It was completed in 2003.
New Era:
Frankly, I believe personalized medicine will bring an end to the “Blockbuster Drug” era. We will no longer see the days of drugs which sell more than $1 billion a year in annual sales.
Now, there will be some blockbusters. They will be for diseases the world doesn’t know relatively much about (i.e. Alzheimer’s disease). But the era when Big Pharma companies need to successfully create the drugs for the masses is coming to an end.
In it, Marcia Angell, former editor of the New England Journal of Medicine, says, “What the big drug companies are doing now are concentrating on lifestyle drugs that can be marketed to vast numbers of people and the market can be easily expanded.”
Andrew Mickey
Chief Investment Strategist
Sphere: Related ContentRelated posts:
Post a Comment